Urigen, Hyaluron To Partner for PBS Combo

Urigen Pharmaceuticals has established a partnerships with Hyaluron Contract Manufacturing (HCM) to develop URG101, Urigen’s proprietary fixed dose combination of FDA-approved drugs targeting painful bladder syndrome (PBS).
 
“Urigen’s development program with Hyaluron is a critical step forward for URG101,” commented William J. Garner, M.D., president and chief executive officer of Urigen. “Hyaluron, with its quality-focused and innovative drug development team, makes an excellent partner for us as URG101 progresses through its development. We look forward to working with the drug development team at Hyaluron to provide a solution to PBS through the commercialization of our product.”
 
“We are very pleased to have been selected by Urigen to undertake the development of their kit targeting PBS,” stated Shawn Kinney, HCM’s president. “The collaborative spirit already demonstrated by both companies’ employees bodes well for a successful development program.”